AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport

International Journal of Cancer

Volumn 133, Issue 6, 2013, Pages 1323-1333

  Samal, Katherine ^a   Zhao, Ping ^a   Kendzicky, Ann ^a   Yco, Lisette P ^b   McClung, Heather ^a   Gerner, Eugene ^c,d   Burns, Mark ^e   Bachmann, André S ^b,f   Sholler, Giselle ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF HAWAII AT HILO   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d Cancer Prevention Pharmaceuticals   (United States)

^e Aminex Therapeutics Inc   (United States)

^f UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

AMXT 1501; DFMO; neuroblastoma; ornithine decarboxylase; polyamine transport

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMXT 1501; CASPASE 3; EFLORNITHINE; ENZYME INHIBITOR; MXT 1501; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ORNITHINE DECARBOXYLASE; POLYAMINE; POLYAMINE TRANSPORT INHIBITOR; RETINOBLASTOMA PROTEIN; RPMI 1640; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; HYPOPHOSPHORYLATION; IC 50; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PROTEIN TRANSPORT;

AMXT-1501; DFMO; NEUROBLASTOMA; ORNITHINE DECARBOXYLASE; POLYAMINE TRANSPORT;

BIOGENIC POLYAMINES; BIOLOGICAL TRANSPORT; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; EFLORNITHINE; ENZYME INHIBITORS; GENES, MYC; HUMANS; NEUROBLASTOMA; ORNITHINE DECARBOXYLASE;

EID: 84879908830     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28139     Document Type: Article

References (31)

1. Park JR, Eggert A, Caron H,. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010; 24: 65-86.
2. Matthay KK,. Targeted isotretinoin in neuroblastoma: kinetics, genetics or absorption. Clin Cancer Res 2013; 19: 311-313.
3. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-16.
4. Brodeur GM,. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16.
5. Gamble LD, Hogarty MD, Liu X, et al. Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma. Front Oncol 2012; 2: 162. doi: 10.3389/fonc.2012.00162. Epub 2012 Nov 16.
6. Bello-Fernandez C, Packham G, et al. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 1993; 90: 7804-8.
7. Wagner AJ, Meyers C, Laimins LA, et al. c-Myc induces the expression and activity of ornithine decarboxylase. Cell Growth Differ 1993; 4: 879-83.
8. Lutz W, Stohr M, Schurmann J, et al. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996; 13: 803-12.
9. Rounbehler RJ, Li W, Hall MA, et al. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 2009; 69: 547-53.
10. Geerts D, Koster J, Albert D, et al. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer 2010; 126: 2012-24.
11. Wallick CJ, Gamper I, Thorne M, et al. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 2005; 24: 5606-18.
12. Bachmann AS, Geerts D, Sholler G,. Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention In:, Hayat E, editor. Pediatric Cancer: Diagnosis, Therapy, and Prognosis: Neuroblastoma. Germany: Springer Company, 2012. p. 91-103.
13. Meyskens FL Jr, Gerner EW,. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999; 5: 945-51. Review.
14. Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 2000: 3878-84.
15. Levin VA, Hess KR, Choucair A, et al. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003; 9: 981-90.
16. Meyskens FL Jr, McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa) 2008; 1: 32-38.
17. Bachmann AS, Levin VA,. Clinical applications of polyamine-based therapeutics. In:, Woster PM, Casero RA Jr, editors. Polyamine drug discovery. Germany: Royal Society of Chemistry, 2012. p. 257-276.
18. Sarhan S, Knodgen B, Seiler N,. The gastrointestinal tract as polyamine source for tumor growth. Anticancer Res 1989; 9: 215-24.
19. Chen Y, Weeks RS, Burns MR, et al. Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma. Int J Cancer 2006; 118: 2344-9.
20. Devens BH, Weeks RS, Burns MR, et al. Polyamine depletion therapy in prostate cancer. Prostate Cancer Prostatic Dis 2000; 3: 275-9.
21. Weeks RS, Vanderwerf SM, Carlson CL, et al. Novel lysine-spermine conjugate inhibits polyamine transport and inhibits cell growth when given with DFMO. Exp Cell Res 2000; 261: 293-302.
22. Burns MR, Graminski GF, Weeks RS, et al. Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor. J Med Chem 2009; 52: 1983-93.
23. Seiler N, Knodgen B,. High-performance liquid chromatographic procedure for the simultaneous determination of the natural polyamines and their monoacetyl derivatives. J Chromatogr 1980; 221: 227-35.
24. Matsuo T, Thiele CJ,. p27Kip1: a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line. Oncogene 1998; 16: 3337-43.
25. Galderisi U, Di Bernardo G, Cipollaro M, et al. Induction of apoptosis and differentiation in neuroblastoma and astrocytoma cells by the overexpression of Bin1, a novel Myc interacting protein. J Cell Biochem 1999; 74: 313-22.
26. Galderisi U, Jori FP, Giordano A,. Cell cycle regulation and neural differentiation. Oncogene 2003; 22: 5208-19.
27. Lu X, Pearson A, Lunec J,. The MYCN oncoprotein as a drug development target. Cancer Lett 2003; 197: 125-30. Review.
28. Koomoa DL, Yco LP, Borsics T, et al. Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 2008; 68: 9825-31.
29. Koomoa DL, Geerts D, Lange I, et al. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. Int J Oncol 2013; 42: 1219-28.
30. Claverie N, Mamont PS,. Comparative antitumor properties in rodents of irreversible inhibitors of l-ornithine decarboxylase, used as such or as prodrugs. Cancer Res 1989; 49: 4466-71.
31. Seiler N,. Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect, Parts 1 and 2: selective enzyme inhibitor and structural analogues and derivatives. Curr Drug Targets 2003; 4: 537-85.